

INDUCED ABORTION

GLOBAL PERSPECTIVE, DEVELOPMENTS AND FUTURE RESEARCH

Helena von Hertzen

UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction

> World Health Organization Geneva, Switzerland


DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH





INCIDENCE OF ABORTION WORLDWIDE

210 million pregnancies, 1999 (projected)





Estimated number of induced abortions, by legal status, percentage of all abortions that are illegal, 1995


Region	No of abortions (millions)			% illegal
	Total	Legal	lllegal	
Total	45.5	25.6	19.9	44
Developed regions Excluding Eastern Europe	10.0 3.8	9.1 3.7	0.9 0.3	9 3
Developing regions Excluding China	35.5 24.9	16.5 5.9	19.0 19.0	54 76
Africa	5.0	N.S.	5.0	99
Asia	26.8	16.9	9.9	37
Europe Eastern Europe	7.7 6.2	6.8 5.4	0.9 0.8	12 13
Latin America	4.2	0.2	4.0	95
Northern America	1.5	1.5	N.S.	N.S.

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH


DÉPARTEMENT SANTÉ ET RECHERCHE GÉNÉSIQUES



ABORTION RATES VARY ENORMOUSLY BY COUNTRY



DÉPARTEMENT SANTÉ ET RECHERCHE GÉNÉSIQUES





Accidental Pregnancies Resulting from Contraceptive Failure Worldwide


Method	Estimated failure rate %	Number of users (millions)	Number of accidental pregnancies (thousands)
Sterilization	0.2-1.0	155	310-1,550
Injectable	0.3-1.0	6	20-60
Intrauterine device	e 1-5	80	800-4,000
Oral contraceptive	1-8	55	550-4,400
Vaginal	4-24	6	240-1,400
Rhythm	10-30	16	1,600-4,800
Other traditional	10-20	42	4,200-8,400
Total		398	8,860-30,310
			(Source: Segal and LaGuardia, 199





ABORTION IN LAW

1.38 billion women 15-44, 1999 (projected)




Only to save a woman's life or not permitted on any grounds
To protect a woman's life or physical health
All of the above plus to protect mental health
All of the above plus socioeconomic grounds
Without restriction as to reason

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH





Known abortions and live births per 1000 women, and deaths attributed to abortion per 1,000,000 women, aged 15-44, Romania, 1955-79



NOTE: Known abortions defined as legally induced abortions plus women admitted to hospitals for aftercare or treatment of complications of spontaneous or illegally induced abortions.




Issues related to access to abortion

- The law and its enforcement
- Attitudes of providers/medical practitioners
- Religious and moral teachings
- Public opinion
- Availability of services





Influence of income and residence on obtaining abortions




HVH_LDN_MAR00/10






Estimated annual incidence of unsafe abortion by UN sub-regions, 1995-2000





Estimated annual mortality due to unsafe abortion by UN sub-regions 1995-2000







Global and regional mortality due to unsafe abortion, 1995-2000

	Estimated number of unsafe abortions (1000s)	Estimated number of deaths due unsafe abortion	Case fatality rate (deaths per 100 unsafe abortion procedures)
World total	20 000	78	3 000 0.4
More developed regions*	900	500	<0.1
Less developed regions	19 000	77	7 500 0.4
Africa	5 000	34	000 0.7
Asia*	9 900	38	3 000 0.4
Europe	900	500	<0.1
Latin America & Caribbean	4 000	5	000 0.1
Oceania*	30	150	0.4

Japan, Australia and New Zealand have been excluded from the regional estimates, but are included in the totals for developed regions

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH





DEATH RATES FROM ABORTION IN DEVELOPING AND DEVELOPED COUNTRIES

Region	Deaths per 100,000		
	abortions		
DEVELOPING ¹	330		
AFRICA	680		
SOUTH - SOUTHEAST ASI	A 283		
LATIN AMERICA	119		
DEVELOPED	0.2-1.2		
¹ Excluding China			

HVH_LDN_MAR00/14

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH





POLICY OPTIONS FOR REDUCING UNSAFE ABORTION

- 1. HIGH QUALITY CONTRACEPTIVE SERVICES – also to adolescents and unmarried
- 2. EDUCATIONAL INTERVENTIONS – sexuality and family life education
- 3. LEGISLATIVE REFORM
- 4. SAFE ABORTION SERVICES





Mortality risks associated with pregnancy and selected health procedures

Procedure	Deaths per 100 000 cases		
	United States of America	Developing Countries*	
Legal abortion	1	4-6	
Female sterilization	4	10-100	
Delivery of live birth	14	250-800	
Cesarean section	41	160-220	
Illegal abortion**	50	100-1000	
Hysterectomy	160	300-400	


* Estimated ** Performed by untrained practitioners or outside medical facilities

Source: Population Crisis Committee, World abortion trends, Briefing Paper No 9 September 1982

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH



DEVELOPMENT OF NON-SURGICAL METHODS





ERMINATION OF EARLY PREGNANCY BY PROSTAGLANDINS

	Comparative study *			Randomized
study**	Sulprostone	Gemeprost	Meteneprost	Sulprostone
Vacuum	aspirat	0.5mg three tion	1mg five times times at 3-h	75 or 60mg with 3-h interval
plus 30 or	intervals		45mg 6 h later	
Complete 94.0%	94%	92%	93%	91.1%
abortion Incomplete 2.8%	e 3%	5%	7%	7.4%
abortion Pregnancy	y 3%	3%	0%	1.5%
3.2% PARTMENT OF REF	PRODUCTIVE HEALTH AN	D RESEARCH	DÉPARTEMENT SANTÉ ET I	RECHERCHE GÉNÉSIQUES



PROSTAGLANDINS: SIDE EFFECTS


 Pain: 100% 30% - 60% -

- Nausea and vomiting: 20% 30%
- Diarrhoea: 20% 60%





Registration of Mifepristone as of January 2000







From ⁵/1988 ⁹/1989 600mg mifepristone + gemeprost 1mg or sulprostone 0.25mg i.m.

Efficacy Time lapse between mifepristone and prostaglandin:

< 36 hours: 36 - 48 hours: > 48 hours:

(p=0.001) <u>Emergency VA or curettage</u> Complete abortion rate:

92.0%
95.8%
93.9%

0.1% (11)





- synthetic analogue of naturally occurring prostaglandin E₁
- approved in > 70 countries (prevention and treatment of gastric and duodenal ulcers)
- safe and well tolerated
- tablets can be kept at room temperature when packed in aluminium blisters






DEP


OUTCOME OF TREATMENT WITH MISOPROSTOL ADMINISTERED ORALLY OR VAGINALLY

	Oral	Vaginal	
	misoprostol misoprostol		
Outcome	(N=130)	(N=133)	
	No. of women (%)		
<i>complete abortion (95)</i>	113 (87)	126	
<i>continued pregnancy</i> 1)	9 (7)	1 (
<i>missed abortion</i> 1)	4 (3)	1 (
Incomplete abortion	département santé et re 4 (3)	CHERCHE GÉNÉSIQUES	

Nean plasma concentrations of misoprostol acid over time with oral and vaginal administration







(Gemzell Danielsson_≯1

300/25



TECHNOLOGY DEVELOPMENT

Nonsurgical Abortion 1. **Dose of Mifepristone** Dose and route administration of Misoprostol Length of gestation Service delivery Acceptability/bleeding **Misoprostol alone regimen?** 2. Surgical Abortion Vacuum aspiration **Routine priming with Misoprostol?**





ACCEPTABILITY OF MEDICAL ABORTION

• quality of abortion services facts related to the int \bigcirc length of gestation (49d/63d/ • current situation: France 34% Scotland 40% Sweden 35% United Kingdom 8%





ADVANTAGES/DISADVANTAGES

- Medical abortion
- no surgery (95-98%)
- no operating room needed
- no anaesthesia (pain killers may be needed)
- more network
- cheaper
- longer procedure

- <u>Surgical abortion</u>
- procedure quicker
- some clients prefer not to know what happens



- requires more trained personnel
- risk of complications performent sante et recurrent sentesioues (surgery, anaesthesia)



PREFERRED REGIMEN?

DAY 1: 200mg mifepristone (one tablet)

DAY 3: 2-4 tablets of 200µg misoprostol vaginally

DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH

DÉPARTEMENT SANTÉ ET RECHERCHE GÉNÉSIQUES



International Conference on Population and Development (ICPD), 1994, Cairo

"Prevention of unwanted pregnancies must always be given the highest priority and every attempt should be made to eliminate the need for abortion"...

..."In circumstances where abortion is not against the law, such abortion should be safe."

